

Product Launch
Sometimes medical advances are relatively straight forward. Moximed’s KineSpring works like a shock absorber in the knee to treat osteoarthritis pain. Halsin launched KineSpring in several EU countries targeting both the medical community and potential patients.
Strategic Counsel
There is much for patients to celebrate when a life saving or life changing treatment becomes available. Perhaps even more significant is when a completely new paradigm is introduced. uniQure’s Glybera became the first gene therapy approved in Europe. Halsin provided communications throughout the approval process.
Clinical Trial Recruitment
A cure for Parkinson’s disease is the goal. To get there, drugs need to be developed and clinical studies conducted. The Michael J Fox Foundation came to Halsin to coordinate the European launch of Fox Trial Finder, an online tool to match volunteers to clinical studies.
Halsin Partners provides communication solutions for the unique business challenges faced by the life science industry – from start up biotech to multi-billion market cap companies.
Translate complex scientific concepts to various target audiences
Communicators of Seminal Firsts
1st German biotech IPO
1st Gene therapy approval
1st Dual US/EU listing
1st RNAi merger
US and EU feet on the ground with local insight and knowledge of “ways of doing things”
Our client service model centers around providing the best team for each project. Whether it’s the launch of a medical device in five European countries or an event at a US scientific conference, we have the right team to ensure success. Our team members are senior consultants and experts in their fields. Each in-country consultant provides the local knowledge on the mood of the industry, the insights and particularities of the media and a sense of “how things work” on the ground.
Contact:
If you are interested in finding out more about the communications services we offer, contact us on info@halsin.com
Location:
96 Kensington High Street
London
W8 4SG, UK